

COMUNICACIÓN CLÍNICA

Chagas disease reactivation in a patient non-Hodgkin's lymphoma

Reactivación de la enfermedad de Chagas en un paciente con linfoma no Hodgkin

M.H. Vicco^{a,b,*}, L.I. César^c, H.M. Musacchio^a, D.O. Bar^c, I.S. Marcipar^a, O.A. Bottasso^d

^a Laboratorio de Tecnología Inmunológica, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Ciudad Universitaria, Santa Fe, Argentina

^b Servicio de Clínica Médica, Hospital J. B "Iturraspe", Santa Fe, Argentina

^c Servicio de Hematología, Hospital J. B. "Iturraspe", Santa Fe, Argentina

^d Instituto de Inmunología, Facultad de Medicina, Universidad Nacional de Rosario, Santa Fe, Argentina

Received 27 February 2014; accepted 14 April 2014

Available online 2 June 2014

Chagas disease is a chronic infection caused by the protozoan *Trypanosoma cruzi* (*T. cruzi*). It has a worldwide distribution affecting at least 8–10 million people. In non-endemic countries, Chagas disease is an emerging illness and has become a public health problem. Most of the patients are asymptomatic, but about 30% of the individuals infected with *T. cruzi* develop clinically relevant syndromes involving the gastrointestinal tract and the heart.¹ Actually, another important complication with poor prognosis is Chagas disease reactivation in relation with immunosuppressive states.²

A 65-year-old man was hospitalized because of multiple bilateral, and painful cervical, axillary and inguinal lymphadenopathies, fever, night sweats and weight loss of two months evolution. In addition to positive serology for *T. cruzi* infection, he suffered arterial hypertension that was treated with angiotensin-converting enzyme inhibitors and chronic Chagas heart disease. He had not received treatment with


anti-*T. cruzi* compounds. Vital signs were within normal range. Routine laboratory tests showed normal hemogram, renal and liver function tests, except increased lactate dehydrogenase (1280 UI/L) and decreased serum albumin levels (2.6 g/dL). Serological tests for HIV were negative. Chest X-ray examination was normal. A twelve-lead electrocardiogram revealed persistent precordial S waves. A 2D and M mode echocardiogram only indicated mild left ventricular hypertrophy. A lymph node biopsy was performed and a diagnosis of non-Hodgkin lymphoma was established. Pre-chemotherapy treatment with dexamethasone (16 mg/day) was instituted. Ten days later the patient suddenly worsened with oliguria, hypotension and sustained ventricular tachycardia. New laboratory tests revealed renal failure with normal values of serum potassium, sodium, calcium and phosphorus. Blood and urine cultures were negative. Direct search for *T. cruzi* in peripheral blood was performed through microscopic examination of buffy coat, yielding positive results. The patient died one day after. Autopsy was not performed.

On admission, a serum sample was collected to assess the levels of antibodies against anti-homogenate parasite, anti-FRA (flagellar repetitive antigen of *T. cruzi*), anti-p2β

* Corresponding author.

E-mail addresses: mvicco@santafe-conicet.gov.ar, mhvicro@outlook.com (M.H. Vicco).





p2B—*Trypanosoma cruzi* ribosomal protein. B13—B13 antigen FRA—flagellar repetitive antigen.
Levels of antibodies were expressed as the ratio between the optical density (OD) of the sample and the OD of the negative standard cut off. This index is referred as IODN (index of the optical density of autoantibodies in relation to the negative control). An IODN ≤ 1 was considered negative 1.
A, levels on admission and B, levels after 10 days of corticosteroid treatment.

Figure 1 Antibody levels after 10 days of immunosuppressive treatment initiation.

(*T. cruzi* ribosomal protein), and anti-B13. A blood sample was also investigated for the direct presence of *T. cruzi*, revealing no parasites. Another blood sample was taken after 10 days of immunosuppressive treatment initiation. Protein expression, purification and measurement of antibodies by immunoassay were performed as described elsewhere.¹ Serum levels of antibodies are shown in Fig. 1.

Chagas disease reactivation is defined as an increase in parasitemia detected by direct parasitological techniques in patients with chronic Chagas disease.² Most common clinical presentations include heart failure due to acute myocarditis, acute onset of malignant ventricular arrhythmias, meningoencephalitis, fever, and involvement of the esophagus, colon and liver. The few reports of Chagas disease reactivation in hematologic neoplasms are mostly associated with blood transfusion administration. Rassi et al.³ described changes in the course of *T. cruzi* infection but only after long-term corticosteroid therapy (46–60 days).^{2–5} Table 1 summarizes published cases reported of Chagas disease reactivation related with hematological neoplasms under chemotherapy.

Non-Hodgkin lymphoma might induce several immunological disturbances affecting cellular and humoral immune response, which might induce Chagas disease reactivation. However, there is no evidence to support oncohematological diseases as a risk factor.² The relevance of our report relies mainly on the rapid onset of Chagas disease reactivation, just after 10 days of corticosteroid treatment, and its poor clinical course. Moreover, this is the first description that refers to the levels of anti-p2β, anti-B13, anti-parasite homogenate and anti-FRA, during Chagas disease reactivation. Anti-p2β and anti-B13 have been shown to play a pathogenic role in the development of heart tissue lesions.¹ While not routinely employed, these antibody measurements may be useful for assessing Chagas disease staging, prognosis and treatment response.^{12–14}

Table 1 Characteristics of reported cases of Chagas disease reactivation in patients with hematological neoplasms undergoing chemotherapy.

Case report	Age (Years)	Sex	Underlying neoplasm	Chemotherapy	Length of time for reactivation	Treatment	Outcome
Francia ⁶	65	Male	LL	NM	N/A	–	Death
Kohl et al. ⁷	14	Female	LL	NM	One month after the first cycle of chemotherapy	Nifurtimox	Survival
Metze ⁸	46	Female	HL	NM	During the induction phase	–	Death
Salgado ⁹	73	Male	LL	Chlorambucil	N/A	Benznidazole	Survival
Fontes Rezende ⁵	42	Female	NHL	CHOP + BLEO	1 month after the last cycle of chemotherapy	Benznidazole	Death
Cohen ¹⁰	16	Female	LL	NM	2 years after the last cycle of chemotherapy. In maintenance therapy with methotrexate and 6-mercaptopurine	Benznidazole	Survival
Oliveira ¹¹	67	Female	NHL	CHOP	After the fourth cycle of chemotherapy	Benznidazole	Death

NM: not mentioned; ALL: acute lymphocytic leukemia; HL: Hodgkin lymphoma; NHL: Non-Hodgkin lymphoma; CHOP: cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone; BLEO: bleomycin.

N/A: not applicable, in both cases the diagnosis of “acute” Chagas disease was done concomitantly with the oncohematological disease.

As depicted in **Table 1**, Chagas disease reactivation usually occurs during chemotherapy, even during the induction phase, like in this case. Only two cases developed Chagas disease reactivation after chemotherapy completion.

There are no consensus guidelines about how to monitor patients with hematological neoplasms with *T. cruzi* infection. Although some authors recommend the use of quantitative polymerase chain reaction (qPCR) for earlier diagnosis of *T. cruzi* reactivation,^{15–17} these studies have been performed in HIV patients and/or in immunosuppressive states due to organ transplantation. Furthermore, qPCR should be validated in large clinical trials.¹⁸ On the other hand, *Argentine consensus on Chagas disease management* does not recommend qPCR for the monitoring of Chagas disease reactivation in patients with malign hematological disorders.¹⁹

The possibility of rapid fatal outcome, as in our case, in patients with Chagas disease reactivation raises the possibility of early treatment with benznidazole or nifurtimox in all patients with positive serology for *T. cruzi* and clinically significant immunosuppression. Anyway, Chagas disease reactivation should always be taken into account if the patient presents compatible symptoms.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

This work was sponsored by the CONICET (Argentinean Research Council) and Universidad Nacional del Litoral, Argentina. M.H.V thanks CONICET for his fellowship. I.S.M and O. A. B. are members of the CONICET career.

References

1. Vicco MH, Bontempi IA, Rodeles L, Yodice A, Marcipar IS, Bottasso O. Decreased level of antibodies and cardiac involvement in patients with chronic Chagas heart disease vaccinated with BCG. *Med Microbiol Immunol*. 2014;203:133–9.
2. Pinazo MJ, Espinosa G, Cortes-Lletget C, Posada Ede J, Aldasoro E, Oliveira I, et al. Immunosuppression and Chagas disease: a management challenge. *PLoS Negl Trop Dis*. 2013;7:e1965.
3. Rassi A, Amato Neto V, de Siqueira AF, Ferrioli Filho F, Amato VS, Rassi Júnior A. Efeito protetor do benznidazol contra a reativação parasitária em pacientes cronicamente infectados pelo *Trypanosoma cruzi* e tratados com corticóide em virtude de afecções associadas. *Rev Soc Bras Med Trop*. 1999;32:475–82.
4. Ferreira MS, Borges AS. Some aspects of protozoan infections in immunocompromised patients – a review. *Mem Inst Oswaldo Cruz*. 2002;97:443–57.
5. Fontes Rezende RE, Lescano MA, Zambelli Ramalho LN, de Castro Figueiredo JF, Oliveira Dantas R, Garzella Meneghelli U, et al. Reactivation of Chagas' disease in a patient with non-Hodgkin's lymphoma: gastric, oesophageal and laryngeal involvement. *Trans R Soc Trop Med Hyg*. 2006;100:74–8.
6. França LC, Lemos S, Fleury RN, Melaragno FR, Ramos HA, Pasternak J. Chronic Chagas disease associated with lymphatic leukemia: occurrence of acute encephalitis as a possible alteration of the immune state. *Arq Neuro-Psiquiatr*. 1969;27:59–66.
7. Kohl S, Pickering LK, Frankel LS, Yaeger RG. Reactivation of Chagas' disease during therapy of acute lymphocytic leukemia. *Cancer*. 1982;50:827–8.
8. Metze K, Lorand-Metze I, De Almeida EA, De Moraes SL. Reactivation of Chagas' myocarditis during therapy of Hodgkin's disease. *Trop Geogr Med*. 1991;43:228–30.
9. Salgado PR, Gorski AG, Aleixo AR, de Barros EO. Tumor-like lesion due to Chagas' disease in a patient with lymphocytic leukemia. *Rev Inst Med Trop São Paulo*. 1996;38:285–8.
10. Cohen V, Ceballos V, Rodríguez N, González C, Marciano B, Dackiewicz N, et al. Chagas' disease as a cause of cerebral mass in a patient with lymphoblastic leukemia in remission. *Arch Argent Pediatr*. 2010;108:134–7.
11. Oliveira LR, Assis LL, Maltos AL, Calil Meire C, Moraes-Souza H. Reativação da doença de Chagas com envolvimento do sistema nervoso central durante tratamento de linfoma não Hodgkin. *Rev Bras Hematol Hemoter*. 2010;32:269–72.
12. Cunha-Neto E, Teixeira PC, Nogueira LG, Kalil J. Autoimmunity. *Adv Parasitol*. 2011;76:129–52.
13. Vicco MH, Ferini F, Rodeles L, Cardona P, Bontempi I, Lioi S, et al. Assessment of cross-reactive h-pathogen antibodies in patients with different stages of chronic chagas disease. *Rev Esp Cardiol*. 2013;66:791–6.
14. Vicco MH, Pujato N, Bontempi I, Rodeles L, Marcipar I, Bottasso O. Increased levels of anti-p2β antibodies and decreased cardiac involvement in patients with progressive chronic Chagas heart disease undergoing β1 selective antagonist treatment. *Can J Cardiol*. 2014;30:332–7.
15. Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jaramillo AM, et al. International study to evaluate PCR methods for detection of *Trypanosoma cruzi* DNA in blood samples from Chagas disease patients. *PLoS Negl Trop Dis*. 2011;5:e931.
16. de Freitas VL, da Silva SC, Sartori AM, Bezerra RC, Westphalen EV, Molina TD, Teixeira AR, et al. Real-time PCR in HIV/*Trypanosoma cruzi* coinfection with and without Chagas disease reactivation: association with HIV viral load and CD4 level. *PLoS Negl Trop Dis*. 2011;5:e1277.
17. Le Loup G1, Ibrahim K, Malvy D. Maladie de Chagas et immunodépression: infection par le VIH et transplantation. *Bull Soc Pathol Exot*. 2009;102:310–8.
18. Lattes R, Lasala MB. Chagas disease in the immunosuppressed patient. *Clin Microbiol Infect*. 2014;20:300–9.
19. Ministerio de Salud de la República Argentina. Enfermedades Infecciosas, Chagas. Guía para el equipo de salud. Dirección de Epidemiología, 2012. Disponible en: <http://www.msal.gov.ar/chagas/index.php/informacion-para-equipos-de-salud/guia-de-diagnostico-y-tratamiento>. Consultado el 26 de marzo de 2014.